Mirati Therapeutics Inc.
Adagrasib
Advanced Cancer
Countdown
24days
Phase 2 readout · Jul 30, 2026
What's at stake
Phase 2 trial results for Adagrasib in Advanced Cancer are due Jul 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT05853575: Phase 2 trial, sponsor Mirati Therapeutics Inc., drug Adagrasib. Primary completion date 2026-07-30 (estimated).”